Showing results (231-240 of 794) with videos related to

Sort By:
Pageof 80
Diabetologia|April 21, 2016
In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and useOlof Eriksson, Maren Laughlin, Maarten Brom, et al.
Acta Medica Austriaca|March 8, 2005
[Diagnosis, therapy and follow-up of diabetic eye diseases]Michael Stur, Stefan Egger, Anton Haas, et al.
Kidney International|April 23, 2002
Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin releaseAlice Schmidt, Johannes Pleiner, Georg Schaller, et al.
Diabetologia|March 1, 2015
Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 surveyDan Ziegler, Andreas Voss, Wolfgang Rathmann, et al.
Physics in Medicine and Biology|October 27, 2018
Ultrasonic fat fraction quantification using in vivo adaptive sound speed estimationMarion Imbault, Marco Dioguardi Burgio, Alex Faccinetto, et al.
European Radiology|June 25, 2025
Ultrasound hepatorenal index for the diagnosis of steatosis in patients with type 2 diabetes: a prospective validation studyMacil Hamadouche, Valérie Vilgrain, Christian Hobeika, et al.
Diabetes/Metabolism Research and Reviews|March 3, 2026
Obesity and Metabolic Syndrome Predict Polyneuropathy Over 5 Years in Recent-Onset Type 2 Diabetes and Normal Glucose ToleranceGundega Sipola, Alexander Strom, Robert Wagner, et al.
Psychoneuroendocrinology|March 12, 2018
Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetesChristian Herder, Andreas Schmitt, Florian Budden, et al.
Diabetologia|October 31, 2021
Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studiesSabrina Schlesinger, Manuela Neuenschwander, Janett Barbaresko, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialMichael Roden, Jianping Weng, Jens Eilbracht, et al.
Pageof 80